Ketan Mehta, Founder and CEO

dafabet online betting | Founder & CEO

Ketan is the founder of Tris Pharma. Under his leadership, Tris Pharma has developed many innovative technologies, launched new products, and established itself as a leader among technology-driven pharmaceutical companies. Ketan’s work at Tris has led to many discoveries and inventions. Before founding Tris Pharma, Ketan worked for Capsugel (formerly a division of Pfizer) in sales, marketing, and business development for eight years. Prior to Capsugel, he spent approximately six years as a pharmaceutical scientist for three different large pharmaceutical companies. Ketan is a pharmacist by education and holds an MS degree in Pharmaceutical Sciences from the University of Oklahoma.

Cheryl Patnick, CAO

Cheryl Patnick | Chief Administrative Officer

Cheryl joined Tris Pharma in 2010 and is responsible for both our Human Resources and Corporate Administration functions. With over 30 years of experience, she excels in developing cultures where leaders create highly engaged teams and companies develop workforces that maintain a high level of productivity during times of change and accelerated growth. Prior to joining Tris Pharma, Cheryl served as president of Capella Consultants LLC, where she led the human resources and management consulting groups and prior to Capella, Cheryl spent more than 15 years at Sovereign Bank, the last seven years as Executive Vice President, Human Resources. She is active in volunteer activities within the Central New Jersey business community and was a recipient of the HR Person of the Year Award from the Society of Human Resources Management. She earned a BS in business administration, summa cum laude, from the University of Richmond, Virginia.

Nicholas Cappuccino, CQO, SVP of Quality and Compliance

Nicholas Cappuccino | Chief Quality Officer, Senior Vice President of Quality & Compliance

Dr. Cappuccino joined Tris in 2021, and as Chief Quality Officer is responsible for all aspects of Tris Quality & Compliance. Nick has over 40 years of experience in the pharmaceutical industry leading Quality and R&D teams as well as working with the US FDA and other global regulatory agencies at both a strategic policy level and at a tactical level for matters of Pharmaceutical Quality, GMP Compliance and Regulatory Affairs. Nick’s depth of experience includes senior leadership roles dafabet sports bettingat Dr. Reddy’s Laboratories, Eagle Pharmaceuticals, Andrx Pharmaceuticals, Sandoz Inc. and Apotex, Inc. Prior to his advancement into leadership roles, Nick also worked for Sanofi (formerly Hoechst -Roussel) Pharmaceuticals, Schering-Plough and Geneva Pharmaceuticals. Nick currently serves as the Chair of the Science Committee for the International Generic and Biosimilar Medicines Association (IGBA) and represents IGBA on the ICH Management Committee and the ICH Assembly. Dr. Cappuccino holds a Ph.D. in Organic Chemistry from Stevens Institute of Technology, Hoboken, NJ, and an MBA from Fairleigh Dickinson University, Madison, NJ.

Peter Ciano, CFO

Peter Ciano | Chief Financial Officer

Peter joined Tris Pharma in April 2010 and leads our licensing and M&A initiatives. Peter brings to Tris a diverse background and an analytical approach steeped in pharmaceutical markets. He is a pharmacist by training and holds an MBA in finance from Rutgers University. After business school, he joined a boutique strategic management consulting firm where he spent six-plus years, serving as Vice President for the last three years. His clients included leading pharmaceutical firms such as Pfizer and Novartis, drug distribution companies, and health system firms. Peter then spent six years at Kos Pharmaceuticals, serving for the last two years as Executive Director of Corporate Development and Business Planning prior to Kos’ acquisition by Abbott Labs.

Thomas Englese, Chief Commercial Officer

Tim Dyer | Vice President, Business and Program Management

Tim joined Tris in 2024 and brings two decades of portfolio management, product planning, executive leadership, and operational excellence experience to Tris from his previous roles in small and medium-size biotech companies (PTC Therapeutics, Edge Therapeutics, SDIX) and large pharmaceutical companies (Pfizer, Otsuka). Most recently, Tim served as SVP of Global Operations and Chief of Staff to the CEO at PTC Therapeutics. Over his tenure, in addition to his Chief of Staff responsibilities and as a member of PTC’s Executive Committee, Tim led the company’s Global Operations Team and global infrastructure group, with responsibility for managing over 20 facilities worldwide. Tim also served as the company’s Corporate Secretary to the Board of Directors. Tim earned his Bachelor of Arts in Government Affairs from Skidmore College, his Master of Science in Regulatory Affairs and Quality Assurance from Temple University, and his Master of Business Administration from New York University’s Stern School of Business.

Thomas Englese, Chief Commercial Officer

Thomas Englese | Chief Commercial Officer

Tom has more than 20 years of experience in domestic and international commercial functions at biopharmaceutical companies across a breadth of therapeutic areas such as pain management, cardiology, liver disease, anesthesia, and critical care. Prior to joining Tris, he was the chief commercial officer at Aziyo Biologics, where he oversaw multiple business units, profitably negotiated commercial partnerships and was a key leader of the company’s successful IPO team. Earlier in his career, he held various positions at Mallinckrodt (formerly Ikaria Inc.), where he was responsible for the North America franchise of several key products, as well as at Baxter, where he spent six years managing business operations and global analytics. Tom earned his Bachelor of Science in Marketing from Villanova University and his Master of Business Administration in Finance from Pennsylvania State University.

Franchesca Fowler, Vice President, General Counsel

Franchesca Fowler | Vice President, General Counsel

Franchesca brings 15 years of dynamic experience to Tris Pharma, most recently serving as the head of legal and compliance, as well as the global associate general counsel, for Demant, a global medical device company based in Copenhagen, Denmark. At Demant, she spearheaded legal and compliance efforts for the company’s subsidiaries in the U.S. spanning retail, manufacturing and diagnostics, as well as fostered a culture of compliance and authenticity within its internal organizations. Prior to Demant, Ms. Fowler supported the GE life science business as a legal deal support leader. Ms. Fowler received her Bachelor of Science in Finance from Fordham University and her Juris Doctor degree from Rutgers Law School.

Joseph Greico, VP of Clinical Development

Joseph Grieco | Vice President of Clinical Development

Dr. Joseph Grieco joined Tris Pharma in September 2022 and as Vice President of Clinical Development. He leads clinical development and pharmacovigilance, informs asset development, and oversees the operational execution of clinical trials. Joe has an extensive background in clinical development programs in multiple therapeutic areas with a focus on severe rare congenital disorders including lysosomal storage disease, genetically based cognitive disorders, seizure and neo-natal conditions dafabet live casinoas well as severe ophthalmological conditions. Prior to his current role at Tris, Joe held roles of increasing responsibility in both biotech and academia. His early work began as an academic neuroscientist studying Alzheimer’s disease and Parkinson’s Dementia with a focus on rare congenital cognitive disorders, specifically Angelman and Fragile X Syndrome. Most notably during this tenure he identified the first candidate medicine for the treatment of Angelman syndrome which led to the first ever clinical trial in this population with a severe unmet need. Dr. Grieco holds a Ph.D. in Neuroscience and a M.S. in Medical Science from the University of South Florida, Tampa, Florida.

James Hackworth, President of Brand Division

James Hackworth | President, Brand Division

James Hackworth, Ph.D., has over 15 years of multi-therapeutic area experience domestically and internationally with an extensive track record in licensing, M&A and partnership transactions, particularly those with a high degree of complexity, pharmaceutical commercialization, and drug development. Most recently, he founded and was President of Park Therapeutics until it was acquired by Tris in April 2021. Prior to founding Park Therapeutics, James held the position of Chief Business Officer at DeepBiome and was Sr. Vice President, Corporate Development and Commercialization Strategy at Shionogi. James holds a Ph.D. in Physics from Columbia University and a B.S. in Physics from The Ohio State University.

Marc Lesnick, Ph.D., Chief Development Officer

Marc Lesnick, Ph.D. | Chief Development Officer

Dr. Lesnick has deep experience in managing global research and development programs from pre-clinical stage through Phase 3. His background spans a number of therapeutic categories including psychiatry, infectious disease, endocrinology, oncology and allergy. Before co-founding Park Therapeutics, Marc held various executive roles at Spruce Biosciences, QED Therapeutics, Cascadian Therapeutics and Shionogi, Inc., among others, where he focused heavily on regulatory affairs and quality assurance, successfully progressing numerous clinical programs through to U.S. FDA and ex-U.S. approvals. Marc received his Bachelor of Science in Biochemistry and Molecular Biology from the University of California at Santa Cruz and completed his Ph.D. in Biology at the University of Oregon.

Alfred Liang, VP of R&D

Alfred Liang | Vice President, Research & Development

Dr. Liang has more than 20 years of experience in the pharmaceutical industry leading high performing R&D teams in the execution of end-to-end formulation and process development in both brand and generic pharmaceutical environments, from conception to commercialization. His broad experience also encompasses drug delivery technology innovation, patent creation, building product portfolio assets and extending product life cycle. Alfred has held positions of increasing management responsibility at Alpharma (King/Pfizer), Actavis (Teva), and most recently at Ferring Pharmaceuticals. He holds a Ph.D. in Pharmaceutical Sciences and a B.S. in Pharmacy, both from Rutgers University. He’s a registered pharmacist in NJ.

Ankit Patel, Head of Operations

Ankit Patel | Head of Operations

Ankit joined Tris in July 2008 and is responsible for all aspects of our operations activities. Ankit joined Tris in the product development department and has taken roles of increasing responsibilities within Tris. He has effectively scaled up and troubleshot products and processes. Prior to joining Tris, Ankit worked in different companies as a pharmacist, a manufacturing chemist in a parenteral department, and a research chemist in a chemical lab. Ankit is a pharmacist by education and holds an MS degree in Pharmaceutical Engineering from the New Jersey Institute of Technology.

Janet Penner, President of Generics Division

Janet Penner | President, Generics Division

Janet joined Tris Pharma in May 2013 and leads the Generics business unit. Bringing a diverse background to Tris, Janet spent the first 12 years of her career working across multiple functional areas within GE and PepsiCo divisions in industries spanning consumer durables, financial services, and hospitality. In 1999 she joined Amerisource, eventually heading up the Generics group for Amerisource and then AmerisourceBergen. Since then, Janet has held senior management positions with smaller and midsized generic pharmaceutical companies. She holds an MBA from the Schulich School of Business at York University and a BA from Western University.

Ben Smeets, Head of IT

Ben Smeets | Head of IT

Ben joined Tris in 2021 to lead Tris’s Information Technology team. In this role he is responsible for all aspects of Tris’s IT infrastructure and Business Applications. Ben has over 40 years of experience, including 20+ years in the pharmaceutical industry with various US and global Business-IT leadership roles covering R&D, Manufacturing, Commercial, Finance and other support functions. In these roles he has been responsible for the dafabet sports bettingdelivery of large-scale business critical applications and innovative solutions, global IT strategy and IT architecture. Most notable in his tenure at Akzo Nobel Coatings, Ben was responsible for the development and launch of a unique and innovative Color Measure and Mixing application for the global Do It Yourself and Car Repair businesses. Prior to joining Tris, Ben worked as Chief Information Officer at Ferring Pharmaceuticals US, Head of Commercial IT innovation at Merck & Co, Global IT portfolio and IT CRM strategy at Schering-Plough and various global roles at Organon and Akzo Nobel in the Netherlands. Ben holds a B.S. in Analytical Chemistry from the Hoge School Fontys, in the Netherlands.

Contact us

Interested in learning more about our products, pipeline, and partnerships?

Required fields are indicated with "*".